ストックスクリーナーアプリを入手
48.76
3.15%
1.4149
前日終値:
$47.35
開ける：
$47.99
24時間の取引高:
74,772
Relative Volume:
0.55
時価総額：
$1.71B
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+13.82%
1か月 パフォーマンス:
+31.43%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$47.73
$49.98
1週間の範囲:
$42.58
$50.85
52週間の値動き範囲:
$32.00
$51.56
Veradermics Inc Stock (MANE) Company Profile
Compare MANE vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MANE
Veradermics Inc
|
48.81 | 1.66B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.85 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.18 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
722.05 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.07 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
293.18 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Veradermics Inc (MANE) 最新ニュース
A Look At Veradermics (MANE) Valuation After Recent Share Price Momentum And DCF Upside Signals - simplywall.st
Veradermics to Participate in Upcoming March Investor Conferences - Business Wire
Veradermics, Incorporated: Revenue and Earnings Analysts Forecasts Revisions | MANE | US9229671048 - marketscreener.com
MANE Technical Analysis & ETF Price Forecast - Intellectia AI
Veradermics, Incorporated: Dividend historical data and projections - marketscreener.com
Leerink initiates Veradermics stock with Outperform rating By Investing.com - Investing.com UK
Cantor Fitzgerald Initiates VeraDermics at Overweight - marketscreener.com
Jefferies Initiates VeraDermics at Buy With $75 Price Target - marketscreener.com
Citigroup Initiates VeraDermics at Buy With $85 Price Target - marketscreener.com
Leerink Initiates VeraDermics at Outperform With $75 Price Target - marketscreener.com
Veradermics eyes FDA first as Jefferies initiates at 'buy'; sees 75% upside on oral hair loss pill - Proactive financial news
Leerink initiates Veradermics stock with Outperform rating - Investing.com Nigeria
Jefferies initiates Veradermics stock with buy rating on phase 3 prospects - Investing.com Canada
Cantor Fitzgerald initiates Veradermics stock with Overweight rating - Investing.com India
NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell – Company Announcement - Financial Times
Longitude investors disclose 12.5% Veradermics (MANE) stake after IPO - Stock Titan
Assessing Veradermics (MANE) Valuation After Recent Share Price Move And Persistent Pre Revenue Losses - Yahoo Finance
Veradermics completes enrollment in second pivotal phase 3 clinical trial of Vdphl01 for male pattern hair loss - marketscreener.com
Veradermics Completes Enrollment in 2nd Phase 3 Study of VDPHL01 for Male Pattern Hair Loss - marketscreener.com
Veradermics completes enrollment in phase 3 trials for hair loss drug - Investing.com Canada
Completion of VDPHL01 Phase 3 Enrollment for Male Pattern Hair Loss - Intellectia AI
Veradermics Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss - Business Wire
Eikon, Agomab raise $350M total in IPOs, sink in aftermarket: Public Equity Report - biocentury.com
Finance Watch: Four IPOs In One Week - Citeline News & Insights
A sign biotech is back? Four drugmakers go public, raising nearly $1 billion in all - statnews.com
Veradermics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering - BioSpace
Veradermics completes $294.8 million IPO with full underwriter option exercise - Investing.com
Veradermics CEO has a great hair day with 122% pop in IPO - Endpoints News
Hair regrowth biotech raises $256m in ‘upsized’ IPO - longevity.technology
Veradermics’ IPO raises $256M in stellar NYSE debut - Hartford Business Journal
Veradermics Raises $256 Million in Upsized Initial Public Offering - Pharmaceutical Executive
A cut above: Veradermics locks in $256M IPO and shares spike - Fierce Pharma
Veradermics announces pricing of upsized IPO - The Pharma Letter
Eikon, Veradermics close IPOs, as Salspera joins queue - pharmaphorum
Ropes Leads Hair-Loss Firm Veradermics' Upsized $256M IPO - Law360
Veradermics, Inc. (MANE): Dermatology Biotech Blasts Off, Eli Lilly and Wellington Anchor Hot IPO - Smartkarma
Baldness Biotech Veradermics Prices $256M IPO for Pivotal Tests of Pill for Hair Loss - MedCity News
Veradermics prices upsized IPO at $17 per share, raises $256.3 million - Investing.com Nigeria
Veradermics, Dermatology-Focused Biopharma Developing Extended-Release Oral Minoxidil for Pattern Hair Loss, Files for NYSE IPO - TradingView
MANE Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
Hair Loss Firm Veradermics Jumps 124% After $256 Million IPO - Bloomberg
No Revenue? No Problem. Biotech Targeting Hair Loss Doubles in Stock IPO. - Barron's
Soaring Veradermics IPO Shows Investor Interest In Hair-Loss Companies Isn’t Thinning - Crunchbase News
Veradermics stock soars 118% in NYSE debut after upsized IPO By Investing.com - Investing.com South Africa
Veradermics stock soars 118% in NYSE debut after upsized IPO - Investing.com
Veradermics stock surges on public debut (MANE:NYSE) - Seeking Alpha
Veradermics soars in NYSE debut after upsized $256.3 million IPO - TradingView
Veradermics opens at $34, IPO priced at $17 per share - TipRanks
Veradermics Shares More Than Double in NYSE Debut - marketscreener.com
Veradermics indicated to open at $20-$22, IPO priced at $17 - TipRanks
Veradermics IPO: $256.3M Raised for Biotech's Hair Restoration Therapy | 2026News and Statistics - IndexBox
Veradermics Inc (MANE) 財務データ
Veradermics Inc (MANE) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
3.96%
大文字化:
|
ボリューム (24 時間):